Close

WT-1

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

  • CAR-MA Vector Products

  • CAR-MA Cell Products

Loading...
  • Target Species:
  • Antibody Clone:
  • Host:
  • Hinge:
  • TM:
  • ICD:
CAT Product Name Target Species Antibody Clone Host Hinge TM ICD Inquiry & Datasheet
CARMA-W1435 Anti-WT-1 (6F-H2) ICD(CD147) CAR-MA Plasmid, pCDCAR1 Human 6F-H2 Mouse IgG1 CD147 CD147   Add to Cart   Datasheet
CARMA-W1436 Anti-WT-1 (6F-H2) ICD(CD86+FcγRI) CAR-MA Plasmid, pCDCAR1 Human 6F-H2 Mouse CD8 CD8 CD86+FcγRI   Add to Cart   Datasheet
CARMA-W1437 Anti-WT-1 (6F-H2) ICD(CD3ζ) CAR-MA Plasmid, pCDCAR1 Human 6F-H2 Mouse CD8 CD8 CD3ζ   Add to Cart   Datasheet
CARMA-W1438 Anti-WT-1 (6F-H2) ICD(Megf10) CAR-MA Plasmid, pCDCAR1 Human 6F-H2 Mouse CD8 CD8 Megf10   Add to Cart   Datasheet
CARMA-W1439 Anti-WT-1 (6F-H2) ICD(FcRɣ) CAR-MA Plasmid, pCDCAR1 Human 6F-H2 Mouse CD8 CD8 FcRɣ   Add to Cart   Datasheet
CARMA-W1440 Anti-WT-1 (6F-H2) ICD(FcRɣ+PI3K) CAR-MA Plasmid, pCDCAR1 Human 6F-H2 Mouse CD8 CD8 FcRɣ+PI3K   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.